NEW YORK (GenomeWeb) – Trovagene today announced a collaboration with City of Hope to explore the clinical utility of the company's Precision Cancer Monitoring platform for detecting and monitoring EGFR mutations in lung cancer patients.
The partners will conduct studies to assess concordance between urinary circulating tumor DNA, blood ctDNA, and tumor tissue for determining EGFR mutational status, Trovagene said, adding they also will evaluate the quantitative and qualitative performance of longitudinal EGFR mutation monitoring with blood and urine samples as it relates to therapy response.
Additionally, Trovagene and City of Hope, a Duarte, Calif.-based hospital and one of the National Cancer Institute's comprehensive cancer centers, will research the feasibility of identifying the TKI-resistant mutation, T790M, in blood and urinary ctDNA at the time of progression, Trovagene said.
"Enabling physicians to detect the emergence of problematic mutations in real time is a key benefit of our Precision Cancer Monitoring platform, and one such mutation is EGFR T790M, which drives treatment resistance in non-small cell lung cancer patients," Trovagene CSO Mark Erlander said in a statement. "This is an important part of our strategy to realize the full potential of our platform, as we partner with major cancer treatment centers in the US to obtain clinical utility data and to integrate our technology into clinical practice."